AU2015312134A1 - Deuterated or a non-deuterated molecule and pharmaceutical formulations - Google Patents

Deuterated or a non-deuterated molecule and pharmaceutical formulations Download PDF

Info

Publication number
AU2015312134A1
AU2015312134A1 AU2015312134A AU2015312134A AU2015312134A1 AU 2015312134 A1 AU2015312134 A1 AU 2015312134A1 AU 2015312134 A AU2015312134 A AU 2015312134A AU 2015312134 A AU2015312134 A AU 2015312134A AU 2015312134 A1 AU2015312134 A1 AU 2015312134A1
Authority
AU
Australia
Prior art keywords
site
deuterated
tetrahydrocurcumin
pharmaceutical formulation
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015312134A
Other languages
English (en)
Inventor
Bhupinder Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2015312134A1 publication Critical patent/AU2015312134A1/en
Priority to AU2019250097A priority Critical patent/AU2019250097A1/en
Priority to AU2021236495A priority patent/AU2021236495A1/en
Priority to AU2023274063A priority patent/AU2023274063A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/04—Saturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/17—Saturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups
    • C07C49/172—Saturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2015312134A 2014-09-02 2015-08-31 Deuterated or a non-deuterated molecule and pharmaceutical formulations Abandoned AU2015312134A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2019250097A AU2019250097A1 (en) 2014-09-02 2019-10-14 Deuterated or a non-deuterated molecule and pharmaceutical formulations
AU2021236495A AU2021236495A1 (en) 2014-09-02 2021-09-22 Deuterated or a non-deuterated molecule and pharmaceutical formulations
AU2023274063A AU2023274063A1 (en) 2014-09-02 2023-11-27 Deuterated or a non-deuterated molecule and pharmaceutical formulations

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462044566P 2014-09-02 2014-09-02
US62/044,566 2014-09-02
PCT/US2015/047822 WO2016036674A1 (en) 2014-09-02 2015-08-31 Deuterated or a non-deuterated molecule and pharmaceutical formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019250097A Division AU2019250097A1 (en) 2014-09-02 2019-10-14 Deuterated or a non-deuterated molecule and pharmaceutical formulations

Publications (1)

Publication Number Publication Date
AU2015312134A1 true AU2015312134A1 (en) 2017-03-23

Family

ID=55401248

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2015312134A Abandoned AU2015312134A1 (en) 2014-09-02 2015-08-31 Deuterated or a non-deuterated molecule and pharmaceutical formulations
AU2019250097A Abandoned AU2019250097A1 (en) 2014-09-02 2019-10-14 Deuterated or a non-deuterated molecule and pharmaceutical formulations
AU2021236495A Abandoned AU2021236495A1 (en) 2014-09-02 2021-09-22 Deuterated or a non-deuterated molecule and pharmaceutical formulations
AU2023274063A Abandoned AU2023274063A1 (en) 2014-09-02 2023-11-27 Deuterated or a non-deuterated molecule and pharmaceutical formulations

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2019250097A Abandoned AU2019250097A1 (en) 2014-09-02 2019-10-14 Deuterated or a non-deuterated molecule and pharmaceutical formulations
AU2021236495A Abandoned AU2021236495A1 (en) 2014-09-02 2021-09-22 Deuterated or a non-deuterated molecule and pharmaceutical formulations
AU2023274063A Abandoned AU2023274063A1 (en) 2014-09-02 2023-11-27 Deuterated or a non-deuterated molecule and pharmaceutical formulations

Country Status (9)

Country Link
US (3) US9375408B2 (https=)
EP (2) EP3628640B1 (https=)
JP (3) JP2017527614A (https=)
CN (1) CN106794986A (https=)
AU (4) AU2015312134A1 (https=)
CA (1) CA2959965A1 (https=)
IL (2) IL285760B2 (https=)
MX (2) MX372723B (https=)
WO (1) WO2016036674A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1888548E (pt) 2005-05-26 2012-10-30 Neuron Systems Inc Derivado de quinolina para o tratamento de doenças da retina
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
CA2898631C (en) 2013-01-23 2023-06-13 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
EP3628640B1 (en) 2014-09-02 2023-08-09 Hub Therapeutics Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment
CN118724806A (zh) 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
US11129823B2 (en) 2016-05-09 2021-09-28 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
WO2017218004A1 (en) * 2016-06-17 2017-12-21 Michael Hudnall Medical food for patients with chronic liver disease
MX2019010576A (es) 2017-03-16 2019-10-07 Aldeyra Therapeutics Inc Compuestos polimorficos y usos de los mismos.
US10934241B2 (en) * 2017-06-16 2021-03-02 University Of North Florida Board Of Trustees Curcuminoid-inspired synthetic compounds as anti-tumor agents
US11117907B2 (en) 2017-06-16 2021-09-14 University Of North Florida Board Of Trustees Curcuminoid-inspired synthetic compounds as anti-tumor agents
JP7311162B2 (ja) 2017-10-10 2023-07-19 アルデイラ セラピューティクス， インコーポレイテッド 炎症性障害の処置
KR20210019459A (ko) * 2018-05-24 2021-02-22 레니버스 테라퓨틱스, 인크. 신장 손상 및 신부전 위험이 있는 환자를 치료하는 방법
WO2020033344A1 (en) 2018-08-06 2020-02-13 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2020181256A1 (en) * 2019-03-06 2020-09-10 Renibus Therapeutics, Inc. Novel tetrahydrocurcumin compositions, methods of making, and methods of using the same
CN113784954A (zh) 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CA3142023A1 (en) * 2019-05-28 2020-12-03 Case Western Reserve University Compositions and methods for preserving dna methylation
JP7422473B2 (ja) * 2019-11-07 2024-01-26 サイビン ユーケー リミテッド 合成方法
CN111017878B (zh) * 2019-12-18 2021-12-17 中国原子能科学研究院 一种用于制备平衡态h2-hd-d2标准气体的装置和方法
WO2021138561A1 (en) * 2019-12-31 2021-07-08 Renibus Therapeutics, Inc. Novel tetrahydrocurcumin compositions, methods of making, and methods of using the same
US11883371B2 (en) * 2020-03-23 2024-01-30 Renibus Therapeutics, Inc. Stress test and treatment of chronic kidney disease
CA3175856A1 (en) 2020-05-13 2021-11-18 Todd Brady Pharmaceutical formulations and uses thereof
AU2021281223A1 (en) 2020-05-27 2023-01-05 Case Western Reserve University Compositions and methods for preserving DNA methylation
CN111759820B (zh) * 2020-08-24 2022-04-19 武汉人福药业有限责任公司 一种奥卡西平片剂及其制备方法
WO2022203674A1 (en) * 2021-03-25 2022-09-29 Majeed, Muhammed Compositions and methods for managing nephropathy

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5276182A (en) 1990-07-09 1994-01-04 The Dow Chemical Company Process for preparing polyurea oligomers
DE4039602A1 (de) 1990-12-12 1992-06-17 Bauer Kurt Heinz Prof Dr Pharmazeutische formulierungen
KR100221695B1 (ko) 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5683676A (en) 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
ES2224200T3 (es) 1992-11-27 2005-03-01 Mayne Pharma (Usa) Inc. Composicion inyectable estable de paclitaxel.
US5654286A (en) 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
CZ301771B6 (cs) 1993-10-01 2010-06-16 Syntex (U.S.A.) Llc. Farmaceutický prostredek ve forme suchého granulátu obsahující mofetil mykofenolát nebo kyselinu mykofenolovou a zpusob jeho prípravy
US5707641A (en) 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5653987A (en) 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US6884429B2 (en) * 1997-09-05 2005-04-26 Isotechnika International Inc. Medical devices incorporating deuterated rapamycin for controlled delivery thereof
US6342507B1 (en) * 1997-09-05 2002-01-29 Isotechnika, Inc. Deuterated rapamycin compounds, method and uses thereof
JPH11246398A (ja) * 1998-03-02 1999-09-14 Kyowa Hakko Kogyo Co Ltd 生体内過酸化脂質増加に起因する疾患の予防または治療剤
US7442720B2 (en) * 2003-12-19 2008-10-28 Omega Bio-Pharma (I.P.3) Limited Compositions and methods for treating diabetes
NZ548195A (en) * 2004-01-14 2011-01-28 Gilead Sciences Inc Lipid-based dispersions useful for drug delivery
US8841326B2 (en) * 2004-02-12 2014-09-23 Stc.Unm Therapeutic curcumin derivatives
CN1283237C (zh) 2004-11-22 2006-11-08 山东大学 姜黄素磷脂复合物及其制备方法
US7776915B2 (en) 2005-03-24 2010-08-17 Tracie Martyn International, Llc Topical formulations and methods of use
AU2006274037B2 (en) * 2005-07-26 2012-04-26 Takeda Gmbh Isotopically substituted pantoprazole
CN101309917B (zh) * 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
JP2007320864A (ja) * 2006-05-30 2007-12-13 Toshihiko Osawa 非アルコール性脂肪肝炎予防・治療用組成物
JP2008133272A (ja) * 2006-10-31 2008-06-12 Ito En Ltd Ｃｐｔ活性亢進剤及び飲食物
JP2008201768A (ja) * 2006-11-24 2008-09-04 Mizu Kk 抗炎症剤及びシクロオキシゲナーゼ阻害剤
WO2008093848A1 (ja) * 2007-02-02 2008-08-07 Sunstar Inc. ホスファチジルコリンを含有する炎症マーカー低減組成物
WO2010097643A1 (en) * 2009-02-24 2010-09-02 Novatech Istrazivanje D.O.O. Formulation based on micronized zeolite, green tea extract, and genistein as a therapeutic agent for reduction of body weight and cellulite
JP5416472B2 (ja) * 2009-05-07 2014-02-12 株式会社セラバリューズ ウコン色素組成物による心機能改善効果
CN101627969B (zh) * 2009-07-30 2011-06-29 浙江工业大学 一种姜黄素自乳化给药系统及其制备
WO2011047309A2 (en) * 2009-10-16 2011-04-21 The Research Foundation Of State University Of New York Treatment of ischemic tissue
CN102526003B (zh) * 2010-01-25 2014-02-19 四川省中医药科学院 四氢姜黄素的用途
CN101732292B (zh) * 2010-01-25 2012-05-16 四川省中医药科学院 四氢姜黄素的用途
WO2011116066A1 (en) * 2010-03-17 2011-09-22 Concert Pharmaceuticals, Inc. Derivatives of dimethylcurcumin
WO2013033250A1 (en) * 2011-09-01 2013-03-07 Xiangping Qian Certain chemical entities, compositions, and methods
CN104739813A (zh) * 2013-12-26 2015-07-01 四川省中医药科学院 四氢姜黄素的新用途
EP3628640B1 (en) * 2014-09-02 2023-08-09 Hub Therapeutics Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment

Also Published As

Publication number Publication date
AU2019250097A1 (en) 2019-10-31
IL285760A (en) 2021-09-30
MX2020005446A (es) 2020-08-27
EP3189007B1 (en) 2019-10-02
JP2021001193A (ja) 2021-01-07
MX372723B (es) 2020-06-19
AU2023274063A1 (en) 2023-12-14
JP2017527614A (ja) 2017-09-21
WO2016036674A1 (en) 2016-03-10
IL250861A0 (en) 2017-04-30
US20200377441A1 (en) 2020-12-03
EP3628640A1 (en) 2020-04-01
IL285760B2 (en) 2025-03-01
CN106794986A (zh) 2017-05-31
US9375408B2 (en) 2016-06-28
CA2959965A1 (en) 2016-03-10
EP3189007A4 (en) 2018-05-16
US20160058713A1 (en) 2016-03-03
IL285760B1 (en) 2024-11-01
US10781158B2 (en) 2020-09-22
IL250861B (en) 2021-09-30
US20170029354A1 (en) 2017-02-02
EP3189007A1 (en) 2017-07-12
JP2023011921A (ja) 2023-01-24
EP3628640B1 (en) 2023-08-09
AU2021236495A1 (en) 2021-10-21
MX2017002750A (es) 2017-08-02

Similar Documents

Publication Publication Date Title
US20200377441A1 (en) Methods of protecting an organ using tetrahydrocurcumin and phosphatidylcholine
KR20130048768A (ko) 레스베라트롤을 함유한 조성물과 그 사용방법.
US8242167B2 (en) Mannose derivatives for killing tumor cells
Wang et al. 2-O-β-D-glucopyranosyl-L-ascorbic acid, a novel vitamin C derivative from Lycium barbarum, prevents oxidative stress
JP2008308479A (ja) 肝臓の保護に用いるベニクスノキタケのシクロヘキサ−２−エノン化合物
WO2016137963A1 (en) Sialylation-increasing therapies for diseases associated with oxidative stress
US20070154540A1 (en) Composition for treatment of osteoarthritis containing apigenin as chondroregenerative agent
EP1800674A1 (en) Agent for preventing metabolic syndrome
KR101566552B1 (ko) 항산화, 항동맥경화 및 항당뇨 효과가 우수한 기능성 리피드
Savsani et al. Cardioprotective effect of flavonoids rich fraction of Premna mucronata on isoproterenol-induced myocardial infarction in Wistar rats
HK40026907A (en) Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment
WO2011027344A2 (en) Combination of vitamin e and beta-glycosphingolipids in compositions and methods for preventing and treating hepatic disorders
US20070129436A1 (en) Agent for Suppressing Body Fat Accumulation
HK40026907B (en) Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment
EP4262429A1 (en) Compositions for targeting receptor for advanced glycation end-products (rage) in a chronic inflammatory condition
KR20100060949A (ko) 신경세포 보호용 조성물
UA66416C2 (en) Method for treating inflammatory and inflammatory-related disorders and normalizing metabolic parameters in blood with the aid of compound consisting of purified yeast rna
AU2002349186B2 (en) Treatment of statin side effects using uridine derivatives
CN112076187B (zh) 安卓锭在制备用于预防或治疗非酒精性脂肪肝的药物中的用途
US20180214463A1 (en) Use of phytic acid or the salts thereof, alone or combined with b6 vitamers, for preventing the formation of advanced glycation end-product
EP3446689B1 (en) Isothiocyanate compound for use in the treatment of hyperbilirubinemia
IT202300006855A1 (it) Composizione per uso orale
Kim Effects of Creatine Monohydrate Supplementation on Cytochrome C and Caspase-9 Expression in Skeletal Muscles from Doxorubicin Treated Rats
Erlinger Propranolol to prevent first bleeding in cirrhosis

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted